CNS neuroscience & therapeutics · 2026
Apoptin-Derived Peptide Alleviates Temporal Lobe Epilepsy (TLE) by Limiting Neuronal Ca2+ Overload Through the HSPA1A-AP2B1 Axis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tan Zixiao, Zhai Qilong, Cui Jingwen, Gao Xiaoying, Liu Xingan, Fan Zhijie, Liu Yu, Sun Jiahang
Аннотация
AIMS: To determine whether the apoptin-derived peptide (also named B9) reduces evoked seizure susceptibility and kainic acid (KA)-associated cognitive and molecular abnormalities, and to define whether these effects involve the heat shock protein family A member 1A (HSPA1A)-adaptor protein complex 2 subunit beta 1 (AP2B1) pathway.
METHODS: The therapeutic efficacy of B9 was examined in a pentylenetetrazol (PTZ)-induced acute seizure model and a KA-induced temporal lobe epilepsy (TLE) model. Electroencephalographic (EEG) recordings were performed to evaluate epileptiform activity. The Barnes maze test was used to assess cognitive function in epileptic mice. Western blotting, co-immunoprecipitation (Co-IP), immunofluorescence (IF), and calcium imaging were used to investigate the underlying mechanism.
RESULTS: B9 reduced seizure susceptibility, attenuated epileptiform activity, and improved spatial learning and memory. HSPA1A was markedly upregulated in TLE-related datasets and experimental models. B9 suppressed the expression of HSPA1A and disrupted its interaction with AP2B1, which restored O-linked β-N-acetylglucosamine (O-GlcNAc) modification and protein stability of AP2B1, preserved GluA2 expression, and limited neuronal Ca2+ overload. Knockdown of AP2B1 abolished the effects of B9 on evoked seizure susceptibility, cognitive performance, GluA2 abundance, and neuronal Ca2+ overload, whereas AP2B1 overexpression reproduced the reductions in PTZ-evoked seizure susceptibility and EEG activity observed with B9.
CONCLUSION: B9 reduces PTZ-evoked seizure susceptibility and ameliorates KA-associated cognitive and molecular abnormalities through modulation of the HSPA1A-AP2B1 axis. These findings support B9 as a potential therapeutic strategy for TLE.
METHODS: The therapeutic efficacy of B9 was examined in a pentylenetetrazol (PTZ)-induced acute seizure model and a KA-induced temporal lobe epilepsy (TLE) model. Electroencephalographic (EEG) recordings were performed to evaluate epileptiform activity. The Barnes maze test was used to assess cognitive function in epileptic mice. Western blotting, co-immunoprecipitation (Co-IP), immunofluorescence (IF), and calcium imaging were used to investigate the underlying mechanism.
RESULTS: B9 reduced seizure susceptibility, attenuated epileptiform activity, and improved spatial learning and memory. HSPA1A was markedly upregulated in TLE-related datasets and experimental models. B9 suppressed the expression of HSPA1A and disrupted its interaction with AP2B1, which restored O-linked β-N-acetylglucosamine (O-GlcNAc) modification and protein stability of AP2B1, preserved GluA2 expression, and limited neuronal Ca2+ overload. Knockdown of AP2B1 abolished the effects of B9 on evoked seizure susceptibility, cognitive performance, GluA2 abundance, and neuronal Ca2+ overload, whereas AP2B1 overexpression reproduced the reductions in PTZ-evoked seizure susceptibility and EEG activity observed with B9.
CONCLUSION: B9 reduces PTZ-evoked seizure susceptibility and ameliorates KA-associated cognitive and molecular abnormalities through modulation of the HSPA1A-AP2B1 axis. These findings support B9 as a potential therapeutic strategy for TLE.